Form 4: Agilon Health Director Receives Equity Grant

Director Karen McLoughlin was granted 2,133 restricted stock units following the company's recent 1-for-25 reverse stock split.

Summary

• Karen McLoughlin, a Director at agilon health, inc., acquired 2,133 restricted stock units (RSUs) on June 2, 2026.
• The RSUs are scheduled to vest in full on June 2, 2027, contingent upon continued service on the board.
• Following this transaction, the reporting person holds a total of 8,207 shares, which includes existing restricted stock units.
• The share totals reflect the impact of a 1-for-25 reverse stock split that was executed on March 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event. While director alignment is positive, the context of the recent heavy reverse split remains a significant overhang on the company's perceived health.

Positives

• Equity-based compensation aligns the interests of the board of directors with long-term shareholder value.
• The one-year vesting cliff encourages director retention and stability within corporate governance.

Negatives

• The 1-for-25 reverse stock split effective March 30, 2026, is a defensive capital structure move often necessitated by significant prior share price declines.

Risks

• The ultimate value of the director's compensation is subject to market volatility and the future performance of AGL common stock.
• The grant is subject to forfeiture if the director ceases service before the June 2027 vesting date.

Future Outlook

The director's equity stake is set to vest in mid-2027, suggesting a commitment to oversee the company's strategic direction through the next fiscal year.

Management Comments

• Restricted stock units vest in full on June 2, 2027, subject to continued service as a director.

Industry Context

StockSavvy.ai notes that agilon health's director compensation structure is typical for the healthcare services industry; however, the massive 1-for-25 reverse split indicates the company has faced significantly more pressure than its peers in the value-based care sector.

Comparison to Industry Standards

• Director equity grants are a standard component of compensation for NYSE and NASDAQ listed healthcare companies.
• The 1-for-25 reverse split ratio is significantly higher than the typical 1-for-5 or 1-for-10 splits seen in the broader market, highlighting extreme historical price correction.

Corporate Governance

Related Party Transactions

• Standard compensation-related equity grant to a member of the Board of Directors.

Stakeholder Impact

• Shareholders are informed of director equity holdings and vesting timelines.
• The company conserves cash by using equity for director compensation.

Next Steps

• Vesting of the granted units on June 2, 2027.

Key Dates

Recommendation

The filing represents routine insider activity. Given the recent 1-for-25 reverse split, investors should maintain a hold position until the company demonstrates that the capital consolidation has successfully stabilized the share price and operational performance.

Keywords

agilon health, AGL, Insider Trading, Restricted Stock Units, Director Compensation, Reverse Stock Split, Healthcare Services, SEC Form 4